NASDAQ:BNGO - Nasdaq - US09075F3055 - Common Stock - Currency: USD
BIONANO GENOMICS INC
NASDAQ:BNGO (1/29/2025, 8:07:09 PM)
After market: 5.16 +0.02 (+0.39%)5.14
+0.07 (+1.38%)
The current stock price of BNGO is 5.14 USD. In the past month the price decreased by -59.21%. In the past year, price decreased by -92.35%.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at the gap up and gap down stocks in today's session.
These stocks are moving in today's session
Bionano Announces Effective Date of Reverse Stock Split...
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.52 | 217.35B | ||
DHR | DANAHER CORP | 29.87 | 161.60B | ||
A | AGILENT TECHNOLOGIES INC | 27.81 | 41.95B | ||
IQV | IQVIA HOLDINGS INC | 18.24 | 35.95B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 35.01 | 28.18B | ||
WST | WEST PHARMACEUTICAL SERVICES | 50.23 | 24.59B | ||
WAT | WATERS CORP | 35.48 | 24.00B | ||
ILMN | ILLUMINA INC | 76.14 | 20.89B | ||
ICLR | ICON PLC | 14.12 | 16.36B | ||
RVTY | REVVITY INC | 26.11 | 15.03B | ||
AVTR | AVANTOR INC | 21.93 | 14.63B | ||
TECH | BIO-TECHNE CORP | 40.13 | 11.41B |
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 344 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
BIONANO GENOMICS INC
9640 Towne Centre Drive, 9640 Towne Centre Drive
San Diego CALIFORNIA 92121 US
CEO: R. Erik Holmlin
Employees: 344
Company Website: https://bionano.com/
Investor Relations: https://ir.bionanogenomics.com/
Phone: 18588887600
The current stock price of BNGO is 5.14 USD.
The exchange symbol of BIONANO GENOMICS INC is BNGO and it is listed on the Nasdaq exchange.
BNGO stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BNGO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BNGO.
BNGO does not pay a dividend.
BNGO does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
The outstanding short interest for BNGO is 17.34% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to BNGO. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months BNGO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by 67.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -155.43% | ||
ROE | -277.86% | ||
Debt/Equity | 0.07 |
ChartMill assigns a Buy % Consensus number of 49% to BNGO. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 64.63% and a revenue growth -19.65% for BNGO